Jessica Nye, PhD

Patients with germline pathogenic variants in BRCA1, BRCA2, and CHEK2 have an increased risk of contralateral breast cancer.

The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.

Interrupting endocrine therapy so patients with breast cancer can attempt pregnancy does not appear to impact short-term disease outcomes.

Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.

Neoadjuvant trastuzumab deruxtecan appears active in patients with HER2-low, hormone receptor-positive, early breast cancer.

Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

Trastuzumab deruxtecan improves outcomes vs physician’s choice of treatment in patients with previously treated, HER2+, advanced breast cancer.

Aromatase inhibitors improved disease-free survival when compared with tamoxifen in HR+, HER2- early breast cancer, regardless of menopausal status.